Tumor Immunologists examine how the immune system interacts with cancer cells and why tumors are often able to evade detection. Cancer cells can suppress immune responses, creating an environment that allows tumors to grow unchecked. By understanding these immune evasion mechanisms, tumor immunologists aim to uncover strategies to stimulate the immune system to recognize and attack cancer cells more effectively. Their research is essential for the development of immunotherapies, which leverage the body's immune system to target cancer cells with greater precision.
One of the most important breakthroughs from tumor immunologists is the development of immune checkpoint inhibitors, which work by blocking proteins that prevent immune cells from attacking tumors. This approach has proven successful in treating cancers such as melanoma, lung cancer, and others. In addition to checkpoint inhibitors, tumor immunologists have advanced the field of adoptive cell therapies like CAR T-cell therapy, where immune cells are modified to better recognize and destroy cancer cells. Additionally, cancer vaccines are being investigated to teach the immune system to identify cancer-specific antigens, further boosting its ability to target and destroy cancer cells. Through these advancements, tumor immunologists are transforming cancer treatment, offering patients more targeted, personalized, and effective strategies for combating the disease.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China